A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Tranexamic acid (Primary)
  • Indications Adhesions; Gastrointestinal disorders; Postoperative ileus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PROFILE
  • Sponsors Leading BioSciences
  • Most Recent Events

    • 07 Sep 2016 According to Leading BioSciences media release, the company has received clearance from the U.S. Food and Drug Administration to initiate this study. The company is now working diligently with it's partners to prepare for this trial and begin recruiting patients."
    • 10 Aug 2016 Leading BioSciences plans to initiate this trial before the end of the year 2016.
    • 22 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top